Physician profile
Tara Troy
NPI 1306825740
$39,573.81
in general payments reported to CMS, 2019-2025
43 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $787 · 2021: $1,220 · 2022: $1,474 · 2023: $2,479 · 2024: $2,519 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $6,768 · Education: $133 · Debt Forgiveness: $84.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,536.67 |
| Food and Beverage | $6,768.25 |
| Education | $133.07 |
| Debt Forgiveness | $84.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $27,536.67 | 2025 | Capsocam Plus |
| Abbvie INC. | $2,478.93 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,652.46 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,597.12 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,410.65 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $684.70 | 2019-2025 | |
| Qol Medical, LLC | $491.58 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $392.41 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $370.94 | 2019-2024 | Sutab, Suflave |
| Ardelyx, INC. | $309.37 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $290.83 | 2024-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $248.10 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $241.10 | 2022-2025 | Dupixent |
| Genzyme Corporation | $182.83 | 2022-2025 | |
| Madrigal Pharmaceuticals | $170.06 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $139.38 | 2019-2023 | Cimzia |
| Daiichi Sankyo INC. | $137.06 | 2021-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $128.04 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $117.93 | 2024-2025 | Vegzelma, Zymfentra |
| Olympus America INC. | $111.21 | 2024-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Merck Sharp & Dohme LLC | $84.31 | 2022-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $80.09 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $76.41 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $70.19 | 2021 | |
| Allergan, INC. | $67.88 | 2019-2020 | |
| Evoke Pharma, INC. | $57.25 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $55.04 | 2019-2020 | |
| Alfasigma USA, INC. | $51.63 | 2020-2021 | |
| Biocon Biologics INC | $51.39 | 2024-2025 | Yesintek, Hulio |
| Novo Nordisk INC | $37.04 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $29.15 | 2023 | |
| Sandoz INC. | $28.36 | 2023 | Hyrimoz |
| Mauna Kea Technologies, INC. | $21.75 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.66 | 2021 | |
| Becton, Dickinson and Company | $20.06 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.25 | 2023 | Rebyota |
| Orphalan INC | $17.78 | 2024 | Cuvrior |
| Eisai INC. | $16.75 | 2019 | |
| Vivus LLC | $16.66 | 2025 | Qsymia |
| Boston Scientific Corporation | $16.01 | 2019 | |
| Redhill Biopharma INC. | $15.57 | 2020 | |
| Mirum Pharmaceuticals, INC. | $15.18 | 2024 | Livmarli |
| Exact Sciences Corporation | $13.03 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Troy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.